Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan
- 12 July 2012
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 120 (2) , 473-476
Abstract
Sixty thalassemia patients (median age, 7 years; range, 1-37) underwent allogeneic hematopoietic stem cell transplantation (HSCT) after a preparation combining thiotepa, treosulfan, and fludarabine. Before HSCT, 27 children were assigned to risk class 1 of the Pesaro classification, 17 to class 2, and 4 to class 3; 12 patients were adults. Twenty patients were transplanted from an HLA-identical sibling and 40 from an unrelated donor. The cumulative incidence of graft failure and transplantation-related mortality was 9% and 7%, respectively. Eight patients experienced grade II-IV acute GVHD, the cumulative incidence being 14%. Among 56 patients at risk, 1 developed limited chronic GVHD. With a median follow-up of 36 months (range, 4-72), the 5-year probability of survival and thalassemia-free survival are 93% and 84%, respectively. Neither the class of risk nor the donor used influenced outcome. This treosulfan-based preparation proved to be safe and effective for thalassemia patients given allogeneic HSCT.Keywords
This publication has 13 references indexed in Scilit:
- Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trialHaematologica, 2011
- Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working partyBone Marrow Transplantation, 2011
- Treosulfan‐based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia majorBritish Journal of Haematology, 2008
- Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myelomaBone Marrow Transplantation, 2007
- New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 yearsBlood, 2004
- Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantationBlood, 2004
- Related umbilical cord blood transplantation in patients with thalassemia and sickle cell diseaseBlood, 2002
- Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypesBlood, 2002
- Marrow Transplantation in Patients with Thalassemia Responsive to Iron Chelation TherapyNew England Journal of Medicine, 1993
- CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,STransplantation, 1974